PFIZER INCPFE
PFIZER INC Financial Overview 2021–2025
Updated Jul 10, 2026Pfizer’s top line underwent a historic compression, shedding $41.8 billion in total revenue between FY2022 and FY2023 as pandemic-era sales evaporated. The core investment case now hinges on the company's ability to replace this massive COVID-19 revenue deficit through aggressive oncology acquisitions and deep cost-cutting before major patent cliffs erode its legacy portfolio.
The total revenue arc highlights this stark transition, falling from $81.3 billion in FY2021 to $62.6 billion in FY2025. However, this top-line decline masks a steady rotation in the core business. While the Comirnaty vaccine accounted for 45% of total revenues in FY2021, Pfizer’s non-COVID portfolio delivered 6% operational growth during FY2025, fueled by expanding cardiovascular and oncology assets like the Vyndaqel family and Padcev. To accelerate this shift, management deployed capital aggressively, executing a $43 billion buyout of Seagen while expanding an enterprise-wide cost realignment program to target $5.7 billion in net savings by 2027.
The market has severely repriced the stock to reflect these transitional risks and upcoming exclusivity losses. After generating $5.47 in EPS during its pandemic peak in FY2022, profitability normalized to an EPS of $1.41 by FY2024. By the close of FY2025, Pfizer traded at just $24.90, reflecting heavy investor skepticism as the company braces for an estimated $1.5 billion revenue impact from patent expirations in 2026.
Recent Developments (Q4 2025 and Q1 2026)
Pfizer offset COVID-19 product declines in Q1 2026 by executing an $8.0 billion acquisition of Metsera to enter the obesity market. Total revenues for the quarter rose 5% year-over-year to $14.45 billion, led by a 41% jump in Nurtec ODT. Profitability contracted as net income dropped 9% to $2.69 billion. This bottom-line compression stemmed from a 25% spike in cost of sales and a 13% increase in research and development expenses.
Management reaffirmed full-year revenue guidance of $59.5 billion to $62.5 billion, alongside the resignation of Chief Financial Officer Dave Denton, effective August 2026. Bulls argue the stock is attractively priced at 18.8x earnings as of the May 5, 2026 reporting date, driven by top-line growth in core therapeutics. Bears warn that escalating operating costs and the 59% and 63% respective drops in Comirnaty and Paxlovid sales will continue pressuring margins.
What to watch: the search for a permanent Chief Financial Officer; pipeline progress from the Metsera assets.
Rev
$63.63B
FY2024
NI
$8.03B
FY2024
EPS
$1.42
FY2024
OCF
$12.74B
FY2024
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
PFIZER INC 8-K Report, Executive Changes (Jun 18, 2026)
Pfizer Inc. (PFE) has filed an 8-K report announcing a significant leadership change within its finance department. Effective August 15, 2026, Chief Financial Officer Dave Denton will step down to pursue an opportunity in the consumer goods sector. The company has emphasized that Mr. Denton's departure is voluntary and not due to any disagreements or concerns regarding Pfizer's financial performance, operations, or accounting practices. In light of Mr. Denton's departure, Pfizer has appointed Cecile Guegan, currently Senior Vice President of Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, 2026. Ms. Guegan, a long-standing Pfizer employee since 2005 with extensive experience in various finance leadership roles within the company, will oversee the CFO responsibilities while a thorough search for a permanent successor is conducted. This transition is a key event for investors to monitor as it may impact financial strategy and investor relations.
PFIZER INC 8-K Report, Regulation FD Disclosure (Jun 18, 2026)
Pfizer Inc. (PFE) filed an 8-K on June 18, 2026, primarily to reaffirm its previously issued fiscal year 2026 financial guidance following the announcement of a Chief Financial Officer transition. The company reiterated its revenue guidance of $59.5 billion to $62.5 billion and its Adjusted Diluted Earnings Per Share (EPS) guidance of $2.80 to $3.00. This reaffirmation suggests that despite the executive change, Pfizer's management remains confident in the company's operational and financial outlook for the remainder of the fiscal year. Investors should note that this filing does not introduce new financial targets but rather confirms existing ones, providing a degree of stability amidst organizational adjustments. The extensive risk factors included in the filing underscore the inherent volatility and uncertainties associated with the pharmaceutical industry.
PFIZER INC 8-K Report, Financial Results (May 5, 2026)
Pfizer Inc. (PFE) has filed a Form 8-K on May 5, 2026, to report its financial results for the first quarter of 2026. The filing primarily incorporates by reference a press release, dated the same day, which details the company's performance and financial condition for the period. Investors should refer to the furnished press release (Exhibit 99) for specific financial data, operational highlights, and management commentary regarding Q1 2026. The 8-K itself serves as notification of the release of this information and does not contain detailed financial statements or disclosures beyond referencing the press release. While this 8-K filing doesn't provide the detailed figures directly within its text, it signals that Pfizer has communicated its Q1 2026 earnings. The furnished press release is the critical document for investors seeking to understand revenue, profitability, segment performance, and any forward-looking guidance or significant business developments announced by Pfizer during the reporting period. The filing also notes the inclusion of an interactive data file for enhanced data accessibility.
PFIZER INC 8-K Report, Shareholder Vote Results (Apr 27, 2026)
Pfizer Inc. (PFE) held its Annual Meeting of Shareholders on April 23, 2026, with the key outcomes being the election of its Board of Directors and the ratification of its independent auditor. All nominated directors received a substantial majority of "For" votes, indicating strong shareholder confidence in the current leadership. Additionally, the selection of KPMG LLP as the independent registered public accounting firm for fiscal year 2026 was overwhelmingly approved. Shareholders also approved the amended Pfizer Inc. 2019 Stock Plan and, on an advisory basis, the compensation of the Named Executive Officers. However, a shareholder proposal to adopt an Independent Chair Policy was not approved, signaling that the majority of shareholders prefer the current board structure. These outcomes reflect a generally supportive shareholder base for Pfizer's governance and executive compensation practices.
PFIZER INC 8-K Report, Financial Results (Feb 3, 2026)
Pfizer Inc. (PFE) has filed an 8-K report on February 3, 2026, to announce its financial results for the fourth quarter of 2025. The report primarily references a press release, filed as Exhibit 99, which contains the detailed financial performance for the quarter. Investors should refer to this press release for comprehensive information regarding Pfizer's operational and financial condition as of the end of 2025. This filing serves as a notification of the release of Q4 2025 earnings and is crucial for understanding the company's recent performance. While the 8-K itself is brief, it directs stakeholders to the accompanying press release for substantive details on revenue, profitability, and any forward-looking statements or guidance provided by the company. Investors are advised to consult Exhibit 99 for a complete picture of Pfizer's financial standing and its outlook.
View all 8-K filings →